The possible use of GLP-1, of GLP-1R analogs, or of inhibitors of dipeptidyl peptidase 4 (DPP4, the GLP-1 degrading enzyme) to treat diabetic retinopathy has been investigated in both in vitro and in vivo models. Here, DPP4 is linked to diabetic retinopathy.